Viewing Study NCT04964895


Ignite Creation Date: 2025-12-24 @ 2:17 PM
Ignite Modification Date: 2025-12-29 @ 11:07 PM
Study NCT ID: NCT04964895
Status: COMPLETED
Last Update Posted: 2025-12-17
First Post: 2021-07-06
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Sexual Quality of Patients After Bladder Cancer Cystectomy
Sponsor: University Hospital, Toulouse
Organization:

Study Overview

Official Title: Sexual Quality of Patients After Bladder Cancer Cystectomy : A Prospective Observational Study
Status: COMPLETED
Status Verified Date: 2023-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: QSCO
Brief Summary: Bladder cancer is the second most prevalent urological cancer in France. About 1 in 5 new cases of bladder cancer infiltrate the muscles. The standard treatment is neoadjuvant chemotherapy followed by radical cystectomy associated with reconstruction of the urinary tract. The short-term effects on well-being and quality of life are well known. The long-term effects are, on the other hand, poorly understood, particularly sexual function. This study aim to asses the quality of sexual life in patients with cystectomy for bladder cancer. This will be done via various questionnaires given before and after surgery.
Detailed Description: The study is a prospective observational cohort study of the quality of sexual life in patients with cystectomy for bladder cancer. Data is collected via Qlq-C30, EORTC-Shq22, MSHQ if male, Female Sexual Function Index (FSFI) questionnaires that the patients complete by themselves. They are given before surgery and then 8 months after surgery.

The study consists of the compilation of relevant clinical data and questionnaire results.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: